Established in 2018, Xellera Therapeutics leads with Hong Kong’s first commercial cGMP facility for cell and gene therapies. We deliver integrated CDMO services—from process development and GMP manufacturing to analytical testing and cryostorage—aligned with US FDA, EMA, and PIC/S standards, advancing ATMPs in Asia. https://www.xelleratherapeutics.com/